Cushing's disease in dogs and humans

Hormone Research

Volumn 71, Issue SUPPL. 1, 2009, Pages 140-143

  De Bruin, C ^a   Meij, B P ^b   Kooistra, H S ^b   Hanson, J M ^b   Lamberts, S W J ^a   Hofland, L J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Animal model; Canine; Corticotroph adenoma; Hypercortisolism; Pituitary

Indexed keywords

CORTICOTROPIN; DOPAMINE 2 RECEPTOR STIMULATING AGENT; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ABDOMINAL OBESITY; ACTH SECRETING ADENOMA; ACTH SECRETING CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONFERENCE PAPER; CUSHING DISEASE; DOG; EXERCISE TOLERANCE; FATIGUE; FEMALE; HUMAN; HYPOPHYSIS ADENOMA; INCIDENCE; MUSCLE ATROPHY; MUSCLE WEAKNESS; NONHUMAN; POLYDIPSIA; PRIORITY JOURNAL; REMISSION;

ANIMALS; DOG DISEASES; DOGS; HUMANS; HYPOPHYSECTOMY; INCIDENCE; PITUITARY ACTH HYPERSECRETION;

EID: 58549104115     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178058     Document Type: Conference Paper

References (16)

1. Orth DN: Cushing's syndrome. N Engl J Med 1995;332:791-803.
2. Etxabe J, Vazquez JA: Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994;40:479-484.
3. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J: Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab 2001:86:117-123.
4. Willeberg P, Priester WA: Epidemiological aspects of clinical hyperadrenocorticism in dogs (canine Cushing's syndrome). J Am Anim Hosp Assoc 1982;18:717-724.
5. Rijnberk A, der Kinderen PJ, Thijssen JH: Spontaneous hyperadrenocorticism in the dog. J Endocrinol 1968;41:397-406.
6. Hanson JM, Teske E, Voorhout G, Galac S, Kooistra HS, Meij BP: Prognostic factors for outcome after transsphenoidal hypophysectomy in dogs with pituitary-dependent hyperadrenocorticism. J Neurosurg 2007;107:830-840.
7. Hanson JM, van't HM, Voorhout G, Teske E, Kooistra HS, Meij BP: Efficacy of transsphenoidal hypophysectomy in treatment of dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2005;19:687-694.
8. van Wijk PA, Rijnberk A, Croughs RJ, Meij BP, Mol JA: Effects of corticotrophin-releasing hormone, vasopressin and insulin-like growth factor-I on proliferation of and adrenocorticotrophic hormone secretion by canine corticotrophic adenoma cells in vitro. Eur J Endocrinol 1998;138:309-315.
9. Bilodeau S, Vallette-Kasic S, Gauthier Y, Figarella-Branger D, Brue T, Berthelet F, Lacroix A, Batista D, Stratakis C, Hanson J, Meij B, Drouin J: Role of Brgl and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev 2006;20:2871-2886.
10. de Bruin C, Hanson JM, Meij BP, Kooistra HS, Waaijers AM, Uitterlinden P, Lamberts SWJ, Hofland LJ: Expression and functional analysis of dopamine D2 and somatostatin receptor subtypes in canine Cushing's disease. Endocrinology 2008 May 15; [E-Pub ahead of print] doi:l0.1210/en.2008-0244.
11. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW: Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004;89:2452-2462.
12. Boscaro M, Petersenn S, Atkinson AB, Bertherat J, Findling J, Snyder P, McBride K, Reincke M, Ludlam W, Gao B, Melmed S, Freda P, Frohman L, Grossman A, Biller B, Glusman JE: Pasireotide (SOM230), the novel multi-ligand somatostatin analogue, is a promising medical therapy for patients with Cushing's disease: preliminary safety and efficacy results of a phase II study. Presented at ENDO 2006, abstract OR9-1, Boston, USA.
13. van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffler P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ: Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 2005;289:E278-E287.
14. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A: The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 2006:91:4482-4488.
15. Hofland LJ, van der Hoek J, Feelders A, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW: The multi-ligand somatostatin analogue SOM 230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005;152:645-654.
16. Heaney AP, Melmed S: Molecular targets in pituitary tumours. Nat Rev Cancer 2004;4:285-295.